Every month I try to read an open-access article. After reading the article, I share the title and associated link with my followers. This is to encourage clinicians to read articles, stay up to date, and continue to grow.
The objective of this paper is to use the “data from the INMARK trial to assess the feasibility and validity of home spirometry as a measure of lung function decline in subjects with IPF “ p2.
Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
By: Imre Noth, Vincent Cottin, Nazia Chaudhuri, Tamera J. Corte, Kerri A. Johannson, Marlies Wijsenbeek, Stephane Jouneau, Andreas Michael, Manuel Quaresma, Klaus B. Rohr, Anne-Marie Russell, Susanne Stowasser and Toby M. Maher
Eur Respir J 2021 58:2001518; published ahead of print 2021,
doi:10.1183/13993003.01518-2020 OPEN ACCESS ARTICLE
Link to the article: http://erj.ersjournals.com/content/58/1/2001518?etoc
Reasons you may find this article interesting
- I like the idea of patients with chronic conditions being able to perform spirometry at home. I value the time and technology advancement to make these tests available at home, and having the ability to remotely tracking patients’ progress. This empowers patients to be more aware of their health status and to be more conscious of their well being.
- Authors conclude that there is a “strong correlation where observed between FVC measurements abstain at home and in clinic at individual time-points, but correlations between changes in FVC measurements over time estimated using home and clinic spirometry were weak, mainly due to variability in the measurements obtained using home spirometry” p8. (side note: researchers did provide re-training as required). I encourage you to read the full article to view all the details.
Happy reading and learning!
August 25, 2021